Stem Cell Sciences, Biofusion to participate in €12 million stem-cell research program

By Lisa Kerner

Charlotte, N.C., Aug. 29 - Stem Cell Sciences plc (SCS) and Biofusion's Axordia Ltd. will participate in a European Commission-approved €12 million stem-cell research program known as Estools.

Four-year goals of the Estools program include developing a complete repertoire of genome engineering techniques for human embryonic stem cells (hES).

The two companies will join academic researchers in the program, led by the University of Sheffield.

"SCS is bringing its technologies and expertise to the project and plans to use any discoveries to supply improved cell-based drug screening and toxicology options to the pharmaceutical and biotechnology industries," scientific program manager Lilian Hook said in the release.

"In the longer term, all these technologies will mesh together to help us deliver new stem-cell therapies."

"The project is important in terms of providing a focal point for further stem cell progress, consolidating the extensive intellectual expertise and enhancing the competitive advantage of the United Kingdom and Europe," Axordia chief executive officer V Paul Gerskowitch added.

Biofusion, an intellectual property commercialization company, holds a 36% share of Axordia and is affiliated with the University of Sheffield.

Axordia is a stem-cell company based in the United Kingdom,

Based in Edinburgh, United Kingdom, SCS is a biotechnology company focused on the development and application of stem-cell technologies in biopharmaceutical research and cell-based therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.